Tag: deep learning

Illustration of a desk with a figure from a recent paper about OncoGAN

OncoGAN Creates Synthetic Cancer Genomes, Opening New Paths for Privacy-Preserving Precision Oncology

On August 30, 2025

This week’s AI ∩ Bio paper covers a recent Cell Genomics paper from the labs of Bo Wang and Lincoln Stein entitled “In silico generation of synthetic cancer genomes using generative AI.”

Summary

Cancer genomics has exploded in the past decade thanks to projects like TCGA and PCAWG, which have sequenced tens of thousands of tumors. These datasets power today’s precision oncology, but they come with a problem: strict privacy rules and limited access mean that few genomes can be freely shared. Enter OncoGAN—a new generative AI framework that creates realistic, privacy-preserving synthetic cancer genomes. Published in Cell Genomics, the study shows how AI can simulate tumor-specific mutation patterns in a way that is both biologically faithful and openly shareable.

Scientific Insight

OncoGAN works by combining different deep learning approaches to generate synthetic genomes that capture point mutations, copy number alterations, and structural variants across eight tumor types. The synthetic genomes successfully reproduce hallmark features such as tobacco- and UV-related mutational signatures, tissue-specific mutation densities, and known driver gene patterns. When tested, these “digital tumors” performed nearly identically to real samples in downstream algorithms like driver detection and tumor-of-origin classification. Importantly, mixing synthetic and real genomes slightly boosted the accuracy of a tumor-type prediction tool—especially for rare cancers where training data is scarce.

Leadership Angle

For diagnostics and biotech organizations, this paper provides a glimpse of how synthetic data can accelerate tool development while navigating the privacy and access barriers that have hounded cancer genomics for years. Synthetic cohorts could help level the playing field for rare cancers, allow fairer benchmarking across companies, and speed up early R&D. The caution: these datasets are complements, not substitutes—real clinical validation remains essential. Leaders should ask not just can we use synthetic data, but where in our pipeline does it add value without creating risk.

AI ∩ Bio

Mentorship Angle

For early-career scientists, this paper is a reminder that technical brilliance isn’t enough. The OncoGAN team shows three habits worth emulating: they (1) designed with interoperability in mind—outputs are in standard formats like VCF; (2) validated their models with external tools, not just their own metrics; and (3) openly stated limitations, from missing low-frequency signatures to not yet modeling subclones. These are the practices that build credibility in science. If you’re starting out, take this as encouragement: your career impact may come not from the flashiest model, but from building rigorous, shareable, and honest tools that push the whole field forward.

Deeper Look

Opportunities to Extend and Deepen the Impact of OncoGAN

The OncoGAN framework marks a timely and technically rigorous advance in synthetic genome generation for cancer research. By combining a variational autoencoder (VAE) and generative adversarial network (GAN), the authors trained on over 23,000 whole-genome sequenced tumor samples to produce synthetic genomes that mimic somatic mutations, copy number alterations, and structural variants across multiple cancer types. This offers a promising route toward generating shareable, privacy-preserving datasets for algorithm development and benchmarking in precision oncology.

That foundation is strong. But to fully realize the promise of OncoGAN—not just as a statistical mimic, but as a biologically faithful tool—several opportunities for deeper analysis and refinement remain.

Interpretable Latent Space Structure

The model’s latent space—where high-dimensional genomic data are compressed into abstract representations—has not been probed for biological meaning. At present, it’s unclear whether the model learns known biological axes of variation (e.g., DNA repair deficiency, chromosomal instability) or simply dominant data trends.

Opportunity: Apply dimensionality reduction (e.g., UMAP) or clustering to the latent vectors and examine whether tumor types, mutation burdens, or known pathways segregate. Interpreting this space could help move OncoGAN from a black-box generator to a tool for uncovering latent structure in cancer genomes.

Regional and Feature-Level Fidelity

Real cancer genomes are heterogeneous—not just across samples, but across regions within each genome. Coding regions, for example, are typically lower entropy and more functionally constrained than intergenic areas, making them easier to learn. Conversely, complex rearrangement zones or repetitive elements may be under-modeled or blurred by the VAE’s compression.

Opportunity: Assess region-specific reconstruction accuracy (e.g., exons vs. telomeric regions) and mutation-type fidelity (e.g., SNVs vs. large structural variants). This would clarify whether OncoGAN preserves biologically important regions or smooths over hard-to-model areas.

Network-Based Validation of Biological Structure

Cancer evolution isn’t random; it follows structured trajectories involving co-occurring and mutually exclusive mutations, often within pathways. These patterns can be lost in aggregate summary statistics.

Opportunity: Construct mutation co-occurrence or pathway activation networks from synthetic genomes and compare them to networks from real tumors. Similar network topology would suggest that OncoGAN learns the structure of cancer mutagenesis—not just global frequencies.

Contrastive Modeling with Non-Cancer Genomes

Currently, the model is trained only on tumor samples. This makes it difficult to determine whether OncoGAN captures tumor-specific signals or just generic mutation distributions.

Opportunity: Incorporate healthy genomes as a contrastive class during training or evaluation. This would allow testing whether synthetic tumors retain discriminative features—e.g., chromosomal instability, elevated mutational signatures—that distinguish cancer genomes from background variation.

Modeling and Filtering of Assay Artifacts

Real sequencing data contain technical noise—from FFPE-induced damage to platform- and batch-specific artifacts—that can be inadvertently incorporated into the training signal. Without careful handling, OncoGAN may learn and reproduce these artifacts as if they were biological features.

Additionally, if the model is trained on processed variant calls (rather than raw sequencing reads), it may inherit systematic biases from upstream bioinformatics pipelines. Regions of the genome that are hard to map, structurally complex, or artifact-prone—such as repetitive elements and telomeric regions—are often underrepresented or excluded entirely. These biases can subtly shape the generative model’s internal assumptions about what defines a “typical” cancer genome.

Opportunity: Include artifact-aware preprocessing, noise injection modeling, or explicit de-noising during training. Downstream validation should also check whether known artifacts (e.g., C>T errors from FFPE deamination) are overrepresented in synthetic genomes. Future directions could also explore alignment-free or graph-based genomic representations to mitigate inherited limitations from short-read pipelines.

Sample Size Sufficiency and Model Saturation

While 23,000 genomes is a large training set, the field lacks evidence that this sample size captures the full spectrum of tumor heterogeneity—or that OncoGAN has reached its capacity limits.

Opportunity: Perform downsampling analyses and learning curves to test when performance saturates. This would clarify how many samples are needed to generate reliable synthetic genomes across both common and rare tumor types.

Closing Note

OncoGAN offers a scalable, technically impressive solution to a pressing problem in cancer genomics. The next step is to elevate it from a tool that statistically resembles real data to one that biologically recapitulates the processes and structures that drive tumor evolution. Doing so will make it not just a data-sharing tool—but a discovery engine.

Illustration of a desk with a figure from a recent paper about Deep-learning-based gene perturbation

When Complexity Misleads

By Kristin Gleitsman

On August 9, 2025

In AI ∩ Bio

In this week’s AI ∩ Bio paper, we look at a multi-dataset benchmark where deep learning models trained to predict single-cell perturbation outcomes did not outperform two deliberately simple baselines: “assume nothing changes” and “predict the additive combination of single perturbations.” Performance improved when models were reduced to just their internal embeddings and a linear decoder—no deep layers, just a direct projection from embedding space to gene expression. In other words, the models had learned biologically meaningful representations during training, but using those representations to make predictions through a complex decoder often made things worse.

This result may not surprise those familiar with traditional machine learning approaches. As the bias–variance tradeoff reminds us: when signal is weak and noise is high, simpler models often generalize better and overfit less, leading them to outperform more complex alternatives.

This study revealed both conditions:

The signal from genetic perturbations is often modest or additive.
The noise in single-cell gene expression is high, due to dropout, amplification bias, and biological variability.

If your model must detect subtle shifts in expression, but your measurement system is saturated with noise, then even an optimal model will struggle to generate meaningful predictions. And a large model may do worse, because it fits spurious correlations that simpler models ignore.

AI ∩ Bio

Before adding more architecture, it’s worth asking:

Have we clearly defined our outcome?
Do we understand the system we are working with?
Can our data realistically support the question we’re asking?

Otherwise, we risk building a computational Rube Goldberg machine: impressive, fragile, and ultimately unclear.

Illustration of a desk with figures from a paper on Cytoland

The Model Isn’t the Magic: How Cytoland shows that domain expertise—not just deep learning—is what makes AI in biology work.

By Kristin Gleitsman

On July 1, 2025

In AI ∩ Bio

This week’s AI ∩ Bio: Reading the Revolution series covers Cytoland, a collection of models for robust virtual staining of landmark organelles across diverse imaging parameters, cell states and types.

The core idea of Cytoland

Cytoland introduces a set of deep learning models for virtual staining—predicting fluorescent labels of key organelles (nuclei, membranes) from label-free microscopy data like quantitative phase images (QPI). These models overcome current limits in generalization, robustness, and data efficiency, offering practical tools for label-free live-cell phenotyping across multiple cell types, imaging setups, and biological contexts.

Basically, the paper introduces a methodology to use AI to predict what a fluorescent image would look like—based only on label-free data (like phase contrast or brightfield). Think of it as teaching the model to “see” the nucleus or membrane without physically tagging them.

Why this matters

Virtual staining isn’t just a cool trick—it can fundamentally shift how we do live-cell imaging, avoiding time and engineering resources to make fluorescent labels for every experiment. And crucially, Cytoland models are open-source, tested on real-world problems, and robust enough to use across microscopes, labs, and cell systems.

In the AI ∩ Bio landscape

This paper is a landmark example of precision engineering, not algorithmic revolution. It does what so many papers fail to do: combine deep learning, physics, and real experimental constraints into a system that’s usable and robust.

You don’t get this kind of robustness without deep domain expertise. You have to understand how microscopes work, what makes a label “missing” vs. “invisible,” and how to design models that hold up in the real world. The magic happens not in the model itself, but at the intersection of thoughtful AI design, careful data collection, and biological insight.

AI ∩ Bio

For early-career scientists

The breakthrough isn’t just in the model—it’s in:

Asking biologically meaningful questions
Collecting the right data
Designing AI that respects the physics and messiness of real experiments

You don’t need to invent new algorithms to do impactful AI ∩ Bio work.

What matters more is:

Understanding what matters biologically (e.g., membranes over time, infection states, tissue development)
Designing training and validation that respects experimental complexity
Building models that generalize to the messiness of real world data

Learn how to ask scientific questions that AI can help answer, and how to design datasets and metrics that hold models accountable to real biological use.

Illustration of a desk with figures from a paper on ConcepPath

From Better Models to Better Questions: A Pathology AI Rethink

By Kristin Gleitsman

On July 1, 2025

In AI ∩ Bio

This week’s AI ∩ Bio: Reading the Revolution series covers ConcepPath, a new framework that blends expert-derived pathology concepts with deep learning to improve both accuracy and interpretability in histopathology image analysis. Instead of relying only on slide-level labels (e.g., “adenocarcinoma”), ConcepPath uses GPT-4 to extract detailed visual concepts from medical literature and aligns them with tissue regions using vision-language models trained on pathology image–text pairs, helping explain predictions in terms that reflect how diagnoses are taught, documented, and defended in clinical practice.

Scientific Approach

Most AI models for whole slide images (WSIs) use Multiple Instance Learning (MIL); they divide slides into patches, analyze each one, and then aggregate the predictions. This works for classification but offers little insight into why a decision was made. NOTE: more on the ‘standard’ approach in the carousel. ConcepPath adds a critical layer: concept alignment. First, GPT-4 infers visual pathology features from peer-reviewed literature—these become expert-informed concepts. The model then learns additional data-driven patterns directly from the images themselves, potentially novel features that improve prediction even if they lack clinical names. These concepts, both known and learned, are aligned with image features using CLIP-style models (Contrastive Language–Image Pretraining, or models that learn to match images and text that describe the same thing). The model then produces similarity maps showing which parts of the tissue match each concept, for example, highlighting keratin pearls in a region suggestive of squamous carcinoma.

These maps improve interpretability, but they do not replicate diagnostic reasoning. Still, this structured mapping makes model outputs more traceable and aligned with how pathologists evaluate slides.

A Step Forward in Trustworthy AI?

ConcepPath signals a strategic evolution in diagnostic AI—from black-box performance to structured, clinically-aligned transparency. While attention maps and saliency overlays are increasingly common, ConcepPath distinguishes itself by embedding domain knowledge into the model architecture itself. It doesn’t just show where the model looked—it tells us what features it saw.

AI ∩ Bio

For early-career researchers, this paper is a reminder that innovation doesn’t always come from better algorithms—it often comes from asking deeper questions. In this case, the authors asked: What would it take for AI to reason with the same visual vocabulary and decision cues as a pathologist? That mindset led to a model that’s both potentially better and more explainable. In computational medicine, it’s this pairing of technical skill and conceptual clarity that sets the stage for meaningful impact.